| A393 |
PAR650097 Biosimilar(Anti-PAR2 Reference Antibody)
Featured
|
|
|
| A394 |
Regeneron patent anti-PAR-2 Biosimilar(Anti-PAR2 Reference Antibody)
Featured
|
|
|
| A395 |
U.Penn. patent anti-PCLA Biosimilar(Anti-PCLA Reference Antibody)
Featured
|
|
|
| A396 |
Recaticimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia. |
|
| A397 |
Ralpancizumab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke. |
|
| A398 |
RG-7652 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A399 |
Lodelcizumab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Lodelcizumab is a monoclonal antibody. Lodelcizumab can be used for the research of hypercholesterolemia. |
|
| A400 |
Ongericimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia. |
|
| A401 |
Tafolecimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia. |
|
| A402 |
Frovocimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9. |
|
| A403 |
Bococizumab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia. |
|
| A404 |
Ebronucimab Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells. |
|
| A405 |
Boehringer anti-PCSK9 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A406 |
Merck patent anti-PCSK9 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A407 |
Schering patent anti-PCSK9 Biosimilar(Anti-PCSK9 Reference Antibody)
Featured
|
|
|
| A408 |
Dostarlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively. |
|
| A409 |
Camrelizumab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al. |
|
| A410 |
Finotonlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research. |
|
| A411 |
Geptanolimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer. |
|
| A412 |
Iparomlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research. |
|
| A413 |
Pidilizumab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research. |
|
| A414 |
Sasanlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells. |
|
| A415 |
Spartalizumab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC). |
|
| A416 |
Pimivalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor. |
|
| A417 |
Toripalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. |
|
| A418 |
Zimberelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. |
|
| A419 |
Prolgolimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma. |
|
| A420 |
Nofazinlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research. |
|
| A421 |
Cetrelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo. |
|
| A422 |
Budigalimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function. |
|
